The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esop…

Esophageal CancerGastric AdenocarcinomaHER2 Gene Mutation

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06123338

Phase 1

A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients

This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose …

Gastric CancerGastrointestinal CancerHER2 Gene Mutation

~Estimated

~$10 – $6,250

Fox Chase Cancer CenterNCT05274048

Phase 2

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradia…

Salivary Gland CancerHER2 Gene Mutation

~Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04620187